Drug profile · INN
apixaban
ELIQUIS
apixaban (ELIQUIS) is a coagulation factor x inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: film coated. Current US regulatory status: approved.
Drug details — apixaban
- US status
- approved
- Class
- Blood and blood forming organs (B01)
- Route
- FILM COATED
- Patents
- 0
- Programs
- 13
- Data quality
- 0.89
Quick answer
apixaban (ELIQUIS) is a coagulation factor x inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: film coated. Current US regulatory status: approved.
Key facts
Mechanism of action
Coagulation factor X inhibitor
Primary target: Coagulation factor X
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is apixaban?
apixaban (ELIQUIS) is a coagulation factor x inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: film coated. Current US regulatory status: approved.
What is the brand name for apixaban?
ELIQUIS is a marketed brand name for apixaban. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of apixaban?
apixaban has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.